Title
Category
Credits
Event date
Cost
Why Now? The New Paradigm and Rising Role of Nuclear Medicine in Alzheimer’s Disease (Credit Expired)
$0.00
OverviewWith the field’s increasing understanding of and ability to manipulate the complex networks of amyloid and tau that drive Alzheimer’s disease (AD), the value of directly visualizing their activity is exponentially rising. The implications for the future of AD diagnosis coupled with the rising potential that disease modifying therapies will reach routine clinical use corresponds to a potentially dramatic increase in the need for nuclear medicine (NM) in this field.
Finding Something in Nothing: Patient-Centered Approaches to Resolve Emotional Blunting in Major Depressive Disorder (Credit Expired)
$0.00
Program Description Emotional blunting (EB) is one of the most highly reported and subjectively disruptive symptoms in patients with major depressive disorder (MDD). As EB can inhibit the ability to achieve full functional recovery in affected patients, proactive screening for and monitoring of this symptom are critical in helping patients achieve complete and sustained improvement in MDD. This CME initiative utilizes expert-led discussion to tackle common challenges and misconceptions in recognizing and resolving EB.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Introductory Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Radiology Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Neurology Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
$0.00
Program DescriptionOver 80% of patients with multiple sclerosis (MS) experience related spasticity. This symptom can be debilitating for both physical and non-physical daily function. Yet, despite the high prevalence and impact of spasticity, a substantial portion of affected patients remain unrecognized and undertreated.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Primary Care Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Across the Spectrum: Transforming the Detection and Management of Disease State Transitions Across the Spectrum of Multiple Sclerosis
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionMultiple sclerosis (MS) is a disease of transitions from subclinical changes to isolated events to definite MS. These clinical developments are often accompanied by changes in disease states ranging from active to inactive. But with increasing recognition that progressive pathologies may begin early in MS, the lines between disease states are beginning to blur.

Pages